Last reviewed · How we verify
NCT06763159
A Study of HS-20124 in Patients with Advanced Solid Tumors
Phase 1 trial testing HS-20124 (Phase Ia：Dose escalation ) in Solid Cancer in 450 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | Hansoh BioMedical R&D Company |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 450 |
| Start date | 30 October 2024 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- HS-20124 (Phase Ia：Dose escalation ) — full drug profile →
- HS-20124 (Phase Ib: Dose expansion) — full drug profile →
Conditions studied
- Solid Cancer — all drugs for Solid Cancer →
Sponsor
Hansoh BioMedical R&D Company — full company profile →
Who can join
18 and older, any sex, with Solid Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
HS-20124 is a novel DAR-8 antibody-drug conjugate （ADC） targeting CDH6. In preclinical studies, it inhibited tumor cell growth expressing CDH6 in vitro and in vivo. The first-in-human trial is conducted to assess the maximum tolerated dose (MTD) and dose limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor activity of HS-20124 in Patients With Advanced Solid Tumors.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06763159
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Solid Cancer
Currently open trials in the same condition.
- NCT07242417 — TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors · EARLY_PHASE1 · recruiting
- NCT07281326 — A Study of AK138D1 in Advanced Malignant Tumors · Phase 1 · recruiting
- NCT06797037 — Proof of Concept to Assess the Feasibility of a Decentralised Pathway Coordinated by the Advanced Practice Nurse for Pat · NA · recruiting
- NCT06771622 — Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · active not recruiting
- NCT06730386 — A Phase I Study of AK138D1 in the Treatment of Advanced Solid Tumors · Phase 1 · recruiting
Other Hansoh BioMedical R&D Company trials
Trials by the same sponsor.
- NCT07464327 — A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With A · Phase 3 · not yet recruiting
- NCT07462923 — HS-20093 in Patients With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma · Phase 1 · recruiting
- NCT07283367 — A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients. · Phase 1, PHASE2 · not yet recruiting
- NCT07186452 — Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid Tumors · Phase 1 · recruiting
- NCT06844799 — A Study of HS-20137 in Participants with Moderate-to-severe Plaque Psoriasis · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06763159 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hansoh BioMedical R&D Company
- Last refreshed: 8 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06763159.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing